BTG3 and rheumatic disorder: Specifically, we show that ANA-positive pediatric patients with an ANA-associated rheumatic disease have a lower prevalence of anti-DFS70 antibodies than patients without an autoimmune or rheumatic disease (17.2 and 46.6%, respectively).